Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C

2002 ◽  
Author(s):  
Takahisa Sakai ◽  
Katsuya Shiraki ◽  
Hidekazu Inoue ◽  
Hiroshi Okano ◽  
Masatoshi Deguchi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Interferon Therapy ◽  
Hbv Genotype ◽  
Genotype C

scholarly journals Observation of genotype C infected chronic hepatitis B patients in clinical practice

2011 ◽  
Vol 5 (12) ◽  
pp. 882-889 ◽  
Author(s):  
Myo Nyein Aung ◽  
Wattana Leowattana ◽  
Noppadon Tangpukdee ◽  
Chatporn Kittitrakul
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Clinical Information ◽  
Hbv Dna ◽  
Hbv Genotype ◽  
Surrogate Outcome ◽  
Treatment Naïve ◽  
Genotype C ◽  
One Year

Introduction: Hepatitis B virus (HBV) genotype C is prevalent in many areas of the world including Thailand and Southeast Asia. It is a strong risk for hepatocellular carcinoma (HCC) by evidence. We aimed to describe the baseline clinical information of treatment naïve genotype C infected chronic hepatitis B (CHB) patients and to describe the treatment response by surrogate outcome markers in genotype C infected CHB patients after one year of nucleos(t)ide analogues (NA) treatment Methodology:  Thirty-four genotype C CHB patients were studied at the Hospital for Tropical Diseases, Bangkok, including 12 patients treated with lamivudine, 11 with telbivudine, 8 with adefovir, and 3 with entecavir. Serum HBV DNA levels, serum alanine amino transferase ( ALT ) levels, HBeAg status, and alpha-feto protein (AFP) levels were recorded at the start and after twelve months of ongoing treatment. HBV genotyping was performed by line-probe assay. Results: About half of the patients (58.8%) were HBeAg positive. Mean HBV viral load was 6.53 + 1.15 log10 copies per ml at baseline and reduced to 3.63 + 1.3 log10 copies per ml after one year of NA treatment. Serum HBV DNA levels became undetectable in 47.1 % of the patients and serum ALT was normalized in 23.5 % of the patients. Conclusion: Most of the genotype C patients were aged above 40 years. More than half of the genotype C infected patients did not achieve virological response and biochemical remission. Among the CHB patients, genotype C infected patients are a high priority group for intervention.

Long-term response to interferon therapy in chronic hepatitis B: importance of hepatitis B virus heterogeneity

1993 ◽  
pp. 171-178
Author(s):  
Teresa Santantonio ◽  
Maria-Christina Jung ◽  
Laura Monno ◽  
M. Milella ◽  
Tiziana Iacovazzi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Interferon Therapy ◽  
B Virus ◽  
Term Response

Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan

2012 ◽  
Vol 47 (7) ◽  
pp. 814-822 ◽  
Author(s):  
Fumitaka Suzuki ◽  
Yasuji Arase ◽  
Yoshiyuki Suzuki ◽  
Norio Akuta ◽  
Hitomi Sezaki ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Interferon Therapy ◽  
Hepatitis B Virus Infection ◽  
Chronic Hepatitis B Virus ◽  
B Virus

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B

2002 ◽  
Vol 123 (6) ◽  
pp. 1812-1822 ◽  
Author(s):  
Vincent di Martino ◽  
Thierry Thevenot ◽  
Jean–François Colin ◽  
Nathalie Boyer ◽  
Michèle Martinot ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Hiv Infection ◽  
Chronic Hepatitis B ◽  
Interferon Therapy ◽  
Term Outcome ◽  
Long Term Outcome
Sign in / Sign up

Export Citation Format

Share Document